EC approves Nivestim for prevention of FN

[News]

Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.

More... (http://www.news-medical.net/news/20100610/EC-approves-Nivestim-for-prevention-of-FN.aspx)